StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.40+0.10 (+0.55%)

Close on Nov 18, 2026Market cap $1.33BP/E 9.3Yield –

Innoviva operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Innoviva's operating income for the twelve months ending Sep 30, 2026 was $170.15M, up 1.3% year over year. For fiscal 2025 it was $163.75M, down 1.9% from the year before. The highest annual figure on record is $375.10M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$163.75M-1.9%
FY2024Dec 31, 2024$166.87M+46.5%
FY2023Dec 31, 2023$113.89M-69.6%
FY2021Dec 31, 2021$375.10M+16.8%
FY2020Dec 31, 2020$321.12M+30.3%
FY2019Dec 31, 2019$246.36M+3.4%
FY2018Dec 31, 2018$238.25M+29.8%
FY2017Dec 31, 2017$183.60M+68.5%
FY2016Dec 31, 2016$108.99M+245.1%
FY2015Dec 31, 2015$31.58M–
FY2014Dec 31, 2014-$33.93M–
FY2013Dec 31, 2013-$28.80M–
FY2012Dec 31, 2012-$25.15M–
FY2011Dec 31, 2011-$109.74M–
FY2010Dec 31, 2010-$78.32M–
FY2009Dec 31, 2009-$81.36M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$42.15M+21.9%
Q2 FY2026Jun 30, 2026$50.86M+4.3%
Q1 FY2026Mar 31, 2026$38.15M-7.9%
Q4 FY2025Dec 31, 2025$38.99M-9.6%
Q3 FY2025Sep 30, 2025$34.58M-20.0%
Q2 FY2025Jun 30, 2025$48.75M-10.9%
Q1 FY2025Mar 31, 2025$41.43M+60.5%
Q4 FY2024Dec 31, 2024$43.14M-47.7%
Q3 FY2024Sep 30, 2024$43.24M-44.4%
Q2 FY2024Jun 30, 2024$54.69M-47.7%
Q1 FY2024Mar 31, 2024$25.81M-72.7%
Q2 FY2022Jun 30, 2022$82.55M-14.5%
Q1 FY2022Mar 31, 2022$77.73M-2.2%
Q4 FY2021Dec 31, 2021$104.53M+23.3%
Q3 FY2021Sep 30, 2021$94.55M+12.0%
Q2 FY2021Jun 30, 2021$96.54M+27.4%
Q1 FY2021Mar 31, 2021$79.48M+4.4%
Q4 FY2020Dec 31, 2020$84.79M+15.1%
Q3 FY2020Sep 30, 2020$84.43M+38.9%
Q2 FY2020Jun 30, 2020$75.79M+26.8%
Q1 FY2020Mar 31, 2020$76.12M+45.9%
Q4 FY2019Dec 31, 2019$73.64M-4.6%
Q3 FY2019Sep 30, 2019$60.79M+5.4%
Q2 FY2019Jun 30, 2019$59.76M-4.7%
Q1 FY2019Mar 31, 2019$52.17M+28.2%
Q4 FY2018Dec 31, 2018$77.22M+16.3%
Q3 FY2018Sep 30, 2018$57.66M+44.1%
Q2 FY2018Jun 30, 2018$62.68M+31.0%
Q1 FY2018Mar 31, 2018$40.70M+38.7%
Q4 FY2017Dec 31, 2017$66.41M+76.3%
Q3 FY2017Sep 30, 2017$40.02M–
Q2 FY2017Jun 30, 2017$47.83M–
Q1 FY2017Mar 31, 2017$29.34M–
Q4 FY2016Dec 31, 2016$37.66M–

More Innoviva figures

See a number that looks wrong?